期刊
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
卷 23, 期 4, 页码 495-501出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.beha.2010.09.012
关键词
acute myeloid leukemia; AML; older; elderly; intensive; age; performance status; karyotype; molecular; gemtuzumab ozogamicin; azacitidine; decitabine; clofarabine; transplantation
类别
资金
- Genzyme
The treatment of older patients with acute myeloid leukemia (AML) has become increasingly important as the population ages. Progress, measured by overall survival rates, has improved in younger patients, perhaps due to the use of intensive post-remission therapies, but it is unclear what will enable progress for older AML patients. The older AML patient population is very heterogeneous, and both patient-specific and leukemia-specific factors must be taken into consideration when choosing the therapy that will most benefit each patient. In addition to standard and intensive chemotherapy regimens, a number of alternative therapies for previously untreated older AML patients are currently being investigated. These include gemtuzumab ozogamicin, azacitidine, decitabine, and clofarabine. (C) 2010 Published by Elsevier Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据